LONG-SHOT TARGETS: +700%, +636%, +527%, AND A +2,757% EXTREME. TARGETS, NOT PROMISES Some of today's target write-ups are eye-watering. Terra Innovatum's $16.50 average of two targets implies about 700% upside from around $2.05. Glass House's $9.50 target implies about 636%. Aligos would need about 2,757% to reach a $60 average target from around $2.10 — a gap that large is a stale-or-dilution warning as much as a bull case. Several of these rest on just one or two analysts. Targets, not promises. +700% for $NKLR. +636% for $GLAS. +527% for $CEPL. +2,757% for $ALGS — yes, you read that right. Extreme targets, thin coverage, and why they may not mean what they look like 👇 1) $NKLR Terra Innovatum Global: The $16.50 central target is the average of just two recent targets — $8 from B. Riley and $25 from H.C. Wainwright, both October 2026. From about $2.05, reaching $16.50 would take a gain of about 700%, huge even by micro-cap standards. Target, not a promise. https://t.co/CPJhkleXwk 2) $GLAS Glass House Brands: The $9.50 target is the average of two October targets ($7 and $12). From about $1.29, reaching $9.50 would take a gain of about 636%. Target, not a promise. https://t.co/qgHAAx3YVB 3) $CEPL Capstone Energy+: The $16.50 target is the average of two verified targets, $13 to $20. From a close near $2.63, that implies about 527% upside. Target, not a promise. https://t.co/qjGKIvMYbf 4) $VENU: The $6.85 target is the average of two verified targets, $5.00 to $8.70. From about $1.10, reaching $6.85 would take a gain of about 520%. Target, not a promise. https://t.co/20ON2zCASc 5) $IMDX Can Insight Molecular Diagnostics: The $10 target is the rounded average of three current targets ($8, $9, and $12). From about $1.86 after a sharp decline, reaching $10 would take a move of more than 400% (the write-up cites about 435%). Target, not a promise. https://t.co/A0iki7ECys 6) $SHAZ SharonAI: The $105 target matches an S&P Global average of six analysts, with a range of about $80 to $124. From about $20, reaching $105 would take a gain of about 420%. Target, not a promise. https://t.co/ziZTI5ZtbR 7) $REA Rare Earths Americas: The $26 target is the average of five verified targets: $12, $25, $28, $30 and $34. From about $5.62, that implies about 363% upside. Target, not a promise. https://t.co/2HLa6Y3k4G 8) $RCAT Red Cat: The $16 target is the average of seven current targets, ranging from about $6 to $25. From a November 16 close of about $3.53, reaching $16 would take a gain of about 350%. Target, not a promise. https://t.co/z43AZj158R 9) $CPHI China Pharma: The $2.00 figure is a fallback from one verifiable analyst rating, not a multi-analyst average. The write-up still cites about 285% upside to $2.00. Target, not a promise — and coverage is extremely thin. https://t.co/7hWrvorvL8 10) $SY So-Young International: The $7.30 target is the average of two verified 12-month targets. From about $1.97, reaching $7.30 would take a gain of about 270%. Target, not a promise. https://t.co/hvEiPtNjR7 11) $TOYO: The $14 central target is the average of two October targets: $10 from Roth MKM and $18 from H.C. Wainwright. That average implies about 230% upside, per the write-up, and the range is wide. Target, not a promise. https://t.co/2YfPAyiQR4 12) $INFQ Infleqtion: The $20 target is the average of seven verified targets, rounded from about $19.57. From about $7.90, reaching $20 would take a gain of about 153%. Target, not a promise. https://t.co/jNdgwbScFw 13) $IAUX i-80 Gold: The $3.25 target is the average of two verified 12-month targets, rounded from $3.24. From a close of about $1.29, that implies about 152% upside. Target, not a promise. https://t.co/jki4yeW2gz 14) $ALGS Aligos Therapeutics: The $60 central target is the average of six verified targets. From about $2.10, Aligos would need a gain of about 2,757% to get there — a gap this large is a stale-or-dilution warning as much as a bull case. Target, not a promise. https://t.co/BYpJoBDpnO Full numbers, catalysts and risks are in each link. Which one are you opening first? Figures are from today's (Nov 16) write-ups, using intraday or latest-close prices, not live quotes. Price targets are targets, not promises. Not investment advice. #pricetarget #stocks #investing #biotech #StockMarket #highrisk
TickeronShare

Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.